ARCTIC Chill Descends On AstraZeneca's Imfinzi/Treme Combo In NSCLC

Failure of the ARCTIC study was considered likely and will do little to dent Imfinzi's overall sales prospects but cools sentiment on the CTLA4 inhibitor tremelimumab.

Wind an clouds over the frozen snow in Lapland, Sweden.
Chill Over Tremelimumab In NSCLC

AstraZeneca PLC's ARCTIC study of its PD-L1 inhibitor/CTLA4 combination of Infimzi (durvalumab) and tremelimumab has failed to produce either a progression-free or survival benefit when used in the late-stage treatment of advanced non-small cell lung cancer (NSCLC) patients, initial data show.

The result was not unexpected following the initial disappointing PFS data for the combination from MYSTIC in first-line metastatic NSCLC...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from R&D

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.